FDA Drug Recall Notice

FDA Drug Recall Notice 2July

Fresenius Kabi Issues Voluntary Nationwide Recall of Two Lots of Fluorouracil Injection Due to the Potential for Glass Particulate

When a company announces a recall, market withdrawal, or safety alert, the FDA posts the company’s announcement as a public service. FDA does not endorse either the product or the company.

Product Photos

Summary

        Company Announcement Date:

         July 01, 2019

Reason for Announcement:
Potential for glass particulate
FDA Publish Date:
July 02, 2019
Company Name:
Fresenius Kabi USA, LLC
Product Type:
Drugs
Generic Drugs
Brand Name:
Fresenius Kabi, Novaplus
Product Description:
Fluorouracil Injection

Company Announcement

Fresenius Kabi USA, LLC is voluntarily recalling two lots of Fluorouracil Injection, USP 5g/100mL (50mg/mL), 100mL fill in 100mL vials, to the user level due to the potential for glass particulate. The affected lots, distributed between December 6, 2018 and February 20, 2019, are listed below:

Product Name/Size NDC Number

Product Code

Lot Number

Expiration Date

First Ship Date

Last Ship Date

Fluorouracil Injection,
USP, 5g/100mL (50mg/mL), 100mL
fill in a 100mL vial
63323-117-69 NP101761 6120341 04-2020 12/06/2018 12/18/2018
63323-117-61

101761

6120420 04-2020 12/07/2018 02/20/2019

Products containing glass particulate should not be administered intravenously due to the potential for life-threatening consequences. Reports in the literature suggest that sequelae of thromboembolism, such as pulmonary emboli, phlebitis, granulomas, or fibrosis may occur.

To date, Fresenius Kabi has not received any complaints or reports of adverse events related to this recall.

The company is issuing this notification after finding glass particulate in five vials in retained sample inventory of lot 6120341 during an inspection for a quality investigation. The second lot (6120420) is included in the recall as a precautionary measure as it was produced in the same filling campaign.

Fluorouracil is a chemotherapy drug that is administered intravenously and indicated for the treatment of a variety of cancers.

Fresenius Kabi is notifying its distributors and customers by letter and asking customers and distributors to check their stock immediately and to quarantine and discontinue the use and distribution of any affected product. Distributors should notify their customers and direct them to quarantine and discontinue distributing or dispensing any affected lots, and to return the product to Fresenius Kabi. The recall letter and response form are available at https://www.freseniusExternal Link DisclaimerExternal Link Disclaimerkabi.com/us/pharmaceuticalExternal Link DisclaimerExternal Link DisclaimerproductExternal Link DisclaimerExternal Link DisclaimerupdatesExternal Link Disclaimer.External Link Disclaimer

Consumers with questions regarding this recall may contact Fresenius Kabi at 1-800-551-7176 Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m. or via email at productcomplaint.USA@fresenius-kabi.com or adverse.events.USA@freseniuskabi.com Consumers should contact their physician or health care provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. For more information about Fresenius Kabi worldwide, please visit www.freseniusExternal Link DisclaimerExternal Link Disclaimerkabi.comExternal Link Disclaimer.External Link Disclaimer


Company Contact Information

Media:
Matt Kuhn
 (847) 550-5751
 matt.kuhn@fresenius-kabi.com

Primary Care

Community Hospital Clinics are located in Wickenburg, Wittmann, and Congress. We sincerely follow our mission to provide quality health and wellness services where the patient, family, and community come first.

Read More

Emergency Care

Our 8 bed Emergency Room department is fully staffed with emergency physicians, nurses, and ER specialists. Your wait time is typically measured in minutes not hours as in the larger metropolitan hospitals.

Read More

Surgical Services

Wickenburg Community Hospital provides a wide variety of surgical care and treatment. We serve a vibrant and active community who favors quality health care close to home.

Read More